Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($1.50), $1.11 worse than the analyst estimate of ($0.39).

“We remain committed to our mission of developing a portfolio of assets with differing mechanisms of action that we believe will form the basis for a functional cure of chronic Hepatitis B", said William Collier, Arbutus’ President and Chief Executive Officer. "Our current efforts are focused on completing the Phase 1a/b clinical trial of AB-729, rapidly selecting a next-generation capsid inhibitor for IND-enabling studies to replace our recently discontinued AB-506, evaluating our oral RNA destabilizer, AB-452, as well as next-generation compounds in this class, and research on compounds that inhibit PD-L1.”

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.